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Introduction
RNA splicing manipulation is a rapidly expanding field of 
research with therapeutically relevant applications in human 
genetic disease.1 Splicing is a suitable intervention point for 
therapy as this approach does not alter the genome and splic-
ing defects are a common molecular etiology in many genetic 
diseases. Among the splice modulating therapies, one of the 
most promising to date involves the use of antisense oligo-
nucleotides (AONs). These have been used to block cryp-
tic splice sites arising from exonic or intronic mutations, to 
induce exon skipping to overcome nonsense or frame-shift 
mutations, to promote therapeutically relevant exon inclusion, 
or to alter exon selection to generate specific isoforms.2 For 
Duchenne muscular dystrophy (DMD), antisense oligonucle-
otides are currently being tested in phase 3 clinical trials in 
patients carrying specific deletions, with the aim of forcing 
exon skipping to restore the open reading frame and recover 
a partially functional dystrophin.3
One of the major initial obstacles to the successful in vivo 
application of antisense therapeutics is the inherent insta-
bility of oligo-deoxynucleotides and their interaction with 
RNAse H which degrades RNA bound in RNA/DNA hetero-
duplexes. To overcome this, different nucleotide chemistries 
have been developed. The most widely used for splicing 
manipulation are phosphorothioates with 2′-O-modifications 
of the ribose residue (2′-O-methyl and 2′-O-methoxyethyl), 
phosphordiamidate morpholinos (PMO), peptide nucleic 
acid, and locked nucleic acid (LNA).4 PMOs have a morpho-
lino ring moiety instead of ribose and phosphorodiamidate 
linkages. They have no charge and do not tend to interact 
with other molecules, which reduces the risk of off-target 
effects but precludes their conjugation with delivery agents 
via electrostatic interaction. Moreover, efficient in vivo use 
has been documented after covalent binding to an octagua-
nidine dendrimer (Vivo-morpholinos (VMOs)).5 LNA are ribo-
nucleotides containing a methylene bridge that connects the 
2′-oxygen of the ribose with the 4′-carbon, providing them 
with an exceptionally high affinity for mRNA and increased 
stability in plasma and in cell culture medium.6 In addition 
to oligonucleotide chemistry, the clinical potential of AON 
treatment for splicing intervention depends on the achieve-
ment of safe and effective delivery to target tissues, biological 
potency and on the avoidance of unwanted side effects, all of 
which are being assayed in animal models as part of preclini-
cal testing studies.7–9
We have investigated the feasibility of antisense therapy 
for deep intronic pseudoexon-activating mutations in different 
inherited metabolic diseases.10,11 Pseudoexons are intronic 
regions with apparent exonic structure having the potential 
for 3′ and 5′ splice site recognition but which are not  normally 
spliced into mRNA. Many of them are derived from Alu or 
LINE elements and are activated by point mutations. These 
pseudoexon activating mutations account for 2–3% of the 
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total alleles in several genetic diseases.12 In the past few 
years, we have demonstrated that AONs can efficiently revert 
pathological pseudoexon insertion in inherited metabolic dis-
eases.11,13–16 Splicing correction was also achieved for exonic 
cryptic splice sites activated by mutations.17 These studies 
have been performed using primary patients’ dermal fibro-
blasts or blood lymphoblasts, where AON treatment resulted 
in efficient splicing correction and recovery of the protein 
and/or enzymatic activity up to normal levels.10
Although these data have established the proof-of-concept 
of the potential of AON treatment for splicing defects in inher-
ited metabolic diseases, methods and strategies for in vivo 
evaluation of its therapeutic efficiency are urgently needed. 
Ideally, animal models with analogous mutations or humanized 
mice with these splice defects may be generated; however this 
is both expensive and cumbersome, and may possibly result 
in lethal enzyme defects, as is the case for KO mice,18,19 mak-
ing it difficult to investigate therapeutic approaches in them. 
Nonetheless, for future clinical studies, animal models are 
necessary tools for developing the experimental protocols for 
translation of therapies from bench to bedside. Here, we have 
studied the in vivo potential of AONs used in different doses 
and routes of delivery as splicing-directed therapy for a liver 
enzyme, using as model targeted exon skipping in the phe-
nylalanine hydroxylase (Pah) gene, resulting in an increase of 
phenylalanine (L-Phe) in body fluids (also termed hyperphe-
nylalaninemia or HPA), as occurs in phenylketonuria (PKU, 
MIM#261600), a well-studied metabolic disease of autosomal 
recessive inheritance. In the liver, PAH metabolizes L-Phe to 
tyrosine (L-Tyr) and its deficiency in humans leads to HPA 
and severe mental retardation unless adequate treatment is 
 implemented.20 Several orthologous mouse models of HPA 
and PKU have been generated by germline mutagenesis, fol-
lowed by molecular characterization.21 The here presented 
Pahenu2 mouse model carries a p.Phe263Ser missense 
mutation in the Pah gene. Wild-type (+/+) and heterozygous 
(Pahenu2/+) mice exhibit normal blood L-Phe concentration 
(<100 µmol/l) while a severe HPA phenotype (blood Phe 
>1,200 µmol/l) arises only in homozygous Pahenu2/enu2 mice.
Our working hypothesis was to use AONs in cellular and 
murine models to target specific exons of the endogenous 
Pah gene resulting in exon skipping of the pre-mRNA and 
thus producing a nonfunctional transcript. It is expected 
that splice suppression of the Pah pre-mRNA will result in a 
decrease in liver (and kidney) PAH activity that can be eas-
ily monitored indirectly by measuring blood L-Phe concen-
tration, now a sensitive biomarker for the effectiveness of 
this antisense treatment. We have used both wild-type and 
Pahenu2/+ mice, both with normal L-Phe levels (<100 µmol/l), 
to test for the efficacy of exon skipping with different AON 
doses. Our results confirm the feasibility of antisense therapy 
for inborn metabolic diseases, involving liver as target organ, 
and providing additional evidence for the use of AONs as 
an antisense method to phenocopy splicing-associated dis-
eases in animals as described.22,23
Results
Exon skipping of PAH pre-mRNA in hepatoma cells
The human PAH gene is composed of 13 constitutively 
spliced exons. A recent report indicated that exon 11 has 
a weak 3′ splice site that is vulnerable to mutations affect-
ing splice-regulatory sequences.24 For antisense-mediated 
splicing, we thus chose to target the 5′ splice site of exon 
11, and for comparison, the 3′ and 5′ splice sites of exon 12, 
which both have a high splicing score (Figure 1). In PKU 
patients, out-of-frame skipping of exon 11 or exon 12 result-
ing from well-characterized PAH mutations c.1066-3C>T 
Figure 1 Antisense oligonucleotides (AONs) used in this study. The figure shows the sequences of human PAH and murine Pah gene 
regions corresponding to exons 11 and 12 and the bases targeted by the different AONs. Exonic sequences are typed in upper case while 
intronic DNA is in lower case. The extension of the various PMO, LNA and VMO sequences are indicated by the black bars. The MaxEnt 
(http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html) scores for the 3′ splice site (3′ss) and 5′ splice site (5′ss) are indicated 
in parentheses.
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or c.1315+1G>A, respectively, is associated with a severe 
HPA phenotype (see http://www.pahdb.mcgill.ca/ or http://
www.biopku.org).
We first analyzed suppression of exon 11 and 12 splic-
ing in vitro using the human hepatoma cell line Hep3B as a 
model. We tested two different commercially available chem-
istries, PMO and LNA, both having high target affinity and 
potent biological activity. The oligonucleotides used to target 
sequences in exons 11 and 12 of the human PAH gene are 
shown in Figure 1. Hep3B cells were transfected with differ-
ent amounts of PMO or LNA (2.5–20 µmol/l) and RT-PCR for 
PAH-mRNA analysis was performed after 24 hours. As can 
be seen in Figure 2a, PMO at doses 2.5–20 µmol/l efficiently 
induced exon 11 skipping resulting in absence of PAH pro-
tein. Using PMO-ex11 at doses lower than 2.5 µmol/l also 
resulted in efficient exon skipping (Supplementary  Figure 
S1). This is in agreement with previous observations in 
human cell lines that exon 11 is vulnerable to skipping.24 In 
fact in some experiments, some amount of exon 11 skipping 
was observed in untreated cells or cells treated with a scram-
bled oligonucleotide (Figure 2a and Supplementary Figure 
S1). For exon 12, only partial skipping was observed for PMO 
targeting the 3′ splice site. The best results were obtained 
using 10–20 µmol/l PMO-ex12b, targeting the 5′ splice site 
 (Figure 2a). On the other hand, LNA targeting exon 11 used 
at the recommended nmol/l concentration range only pro-
duced partial exon skipping (Figure 2c), although we con-
firmed that cells were readily transfected (93–95%) using a 
fluorescent LNA (data not shown).
Exon skipping of Pah pre-mRNA in mice
Our results, along with the reported risk of hepatotoxicity and 
lower sequence specificity for LNA,25,26 prompted us to focus 
on administering morpholino antisense oligonucleotides to 
mice targeting exons 11 and 12 of the Pah gene. To ensure 
efficient delivery, we used VMO, in which the morpholinos 
are covalently linked to an octaguanidine dendrimer allowing 
transport across cell membranes after systemic delivery.27 
Although only recently described in the literature,28 intrave-
nous (i.v.) injection of VMO was observed in our experiments 
to be associated with high toxicity (see Methods section) 
which limited the number of mice to a low number of animals 
per condition tested.
Initially, we tested VMO against exon 11 in wild-type mice, 
which were injected i.v. with 10 or 12.5 mg/kg daily doses for 
two or four consecutive injections, resulting in total doses of 
20, 25, or 50 mg/kg (n = 1 per dose). All mice were eutha-
nized and analyzed 4 days after the first injection. As can be 
seen in Figure 3, RT-PCR analysis of Pah-mRNA revealed 
that nearly complete exon 11 skipping was achieved after 
four consecutive i.v. injections of 12.5 mg/kg per day which 
is equivalent to a total of 50 mg/kg of VMO-ex11. Western 
blot analysis confirmed decreasing amounts of liver PAH pro-
tein while blood L-Phe levels were moderately elevated at the 
maximal VMO dose of 50 mg/kg (297 µmol/l; normal blood 
L-Phe concentration < 100 µmol/l).These results indicated 
that in wild-type mice repeated daily injections of relatively 
high amounts of VMO would be needed to achieve and main-
tain elevated blood L-Phe concentration, our highly sensitive 
biomarker for the efficiency of antisense treatment.
For all subsequent experiments, we thought to test exon 
skipping therapy in heterozygous Pahenu2/+ mice, which 
exhibit pre-existing partial liver PAH deficiency but retain 
normal blood L-Phe, as VMO treatment would have a 
greater likelihood of suppressing liver PAH activity to below 
5% wild-type activity and may more adequately mimic the 
Figure 2 Antisense treatment of Hep3B cells for suppression of human PAH. Analysis of exon 11 and exon 12 splice suppression by 
using different concentrations of PMO-ex11, PMO-ex12a and PMO-ex12b in human Hep3B cells, are shown by (a) end point RT-PCR of 
PAH-mRNA, indicating the estimated percent of exon skipping and (b) western blot of PAH. The lower panel in (b) shows α-tubulin as loading 
control. (c) RT-PCR analysis in untreated cells and cells treated with different amount of LNA-ex11. The identity of the DNA-bands is shown 
schematically on the right. SC, scrambled oligonucleotide.
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hyperphenylalaninemic phenotype of PKU. Pahenu2/+ mice 
(n = 1) were first treated with different doses of VMO-ex11, 
and blood L-Phe concentration was measured daily up to day 
4 after the first injection. A single i.v. injection of 12.5 mg/kg 
showed no increase in blood L-Phe, correlating with residual 
PAH protein and activity in the range of 5–6% of normal wild-
type activity (data not shown).
The effect of two consecutive i.v. injections with different 
doses of VMO-ex11 is shown in Figure 4. Four days after the 
first injection, L-Phe levels remained at normal levels (100–
140 µmol/l) at a total dose of 12 or 20 mg VMO/kg, whereas in 
mice treated with 25 mg/kg, L-Phe levels rose to 1,144 µmol/l 
(Figure 4b) which corresponds closely to the defined severe 
phenotype of HPA or phenylketonuria.20 The observed L-Phe 
levels correlated well with the results in liver analysis, where 
only trace amounts of normal Pah transcript, PAH protein and 
enzyme activity could be detected at the maximal dose used 
(Figure 4c–e). Furthermore, the effect was transient, as exon 
skipping levels diminished after day four and L-Phe concen-
tration were normal from day 6 on (Supplementary Figure 
S2). Both alleles in the heterozygous Pahenu2/+ mice respond 
in the same way to VMO treatment, as sequence analysis of 
the normal and exon skipped band revealed that both peaks 
at the enu2 mutation locus (c.789T>C) are similarly repre-
sented, excluding any preferential targeting of one of the two 
transcripts (data not shown).
We also evaluated the dosing regime needed to maintain 
the HPA phenotype. Suppression of blood L-Phe clearance by 
VMO-induced exon skipping of Pah pre-mRNA depends not 
only on the rate of Pah-gene expression, but also on the turn-
over rates of VMO, Pah-mRNA and PAH protein. As depicted 
in Figure 5, we found that after injection of two initial doses of 
12.5 mg/kg of VMO-ex11 into Pahenu2/+ mice, consecutive dos-
ing every 4 days with 12.5 mg/kg were necessary to maintain 
blood L-Phe levels between 700 and 1,100 µmol/l, equivalent 
to a mild phenylketonuria phenotype (for a definition see).20
Comparison of routes of delivery and targeting various 
Pah-exons
Using the “optimal” dosage and a regime of two consecu-
tive 12.5 mg/kg VMO-Ex11 injections (12.5 mg VMO/kg per 
injection for a total of 25 mg/kg) with euthanasia and tissue 
analysis 4 days after initial injection, we evaluated the effi-
cacy of intraperitoneal (i.p.) delivery of VMO. With i.p. deliv-
ery, we observed only partial exon skipping, translating into 
20% residual PAH activity and L-Phe levels within the normal 
range (<100 µmol/l; data not shown).
In addition, we compared the efficiency of VMO targeting 
exon 12 or exon 11 delivered by i.v. injection. As shown in 
Figure 6, we obtained comparable results with either VMO-
Ex11 or VMO-Ex12 including efficient exon skipping, PAH 
suppression, and elevated blood L-Phe concentration.
Figure 3 Antisense treatment in wild-type mice leads to HPA. Normal wild-type mice (n = 1) were treated with two consecutive daily i.v. 
injections of 10 and 12.5 mg/kg, corresponding to 20 and 25 mg/kg total dose, respectively, or with four consecutive injections of 12.5 mg/kg 
of VMO-ex11(total dose of 50 mg/kg). At day 4 after the first injection, mice were sacrificed for analysis, as shown schematically in (a). (b) 
RT-PCR analysis of Pah-mRNA in liver showing the identity of the bands on the right and the estimated percent of exon skipping. (c) Western 
blot analysis showing PAH protein levels in liver. Note that the faint upper band represents ubiquitinated (Ub) PAH.45 The lower panel shows 
β-actin as loading control. (d) PAH enzyme activity in liver extracts relative to untreated wild-type levels (=100%), and (e) blood L-Phe levels 
(mean ± SD) determined at day 4.
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Suppression of Pah expression in the kidney
In mice, Pah is mainly expressed in liver but there is also 
considerable expression in kidney29 (Supplementary 
Figure S3). We analyzed Pah-mRNA, as well as PAH pro-
tein and enzyme activity in Pahenu2/+ mice subjected to differ-
ent treatment regimes. As shown in Figure 7, we observed 
equal effects whether targeting exon 11 or exon 12, and we 
confirmed that i.p injection of VMO is less effective than i.v. 
injection. Moreover, a single i.v. injection with 12.5 mg VMO/
kg was sufficient to result in complete exon skipping and 
absence of PAH protein in kidneys of treated mice.
Discussion
Experimental evidence in both cell and animal models has 
shown that antisense-mediated splicing modulation can 
result in therapeutically favorable transcripts for a variety 
of genes including dystrophin, SMN, and lamin.1 In this 
work, we provide for the first time in vivo evidence of the 
feasibility of the approach for targeting expression of a liver 
enzyme. For specific disease causing mutations that lead 
to faulty mRNA splicing, splice modulation may be used to 
correct the fault, as has been demonstrated through anti-
sense treatment of patient fibroblasts.10 Alternatively, splice 
modulation can be used to model inborn errors of metab-
olism by interfering with native enzyme expression as we 
have demonstrated here. Likely disease targets include any 
inborn error of metabolism caused by deficiency of a hepatic 
enzyme, such as an aminoacidopathy, organic acidemia, or 
urea cycle disorder. For example, pathological pseudoexon 
insertions have been described in ornithine transcarbamy-
lase deficiency,30,31 6-pyruvoyl-tetrahydropterin synthase 
deficiency where antisense therapy efficiently suppressed 
Figure 4 Antisense treatment in heterozygous Pahenu2/+ mice. (a) Mice (n = 1) were treated with two consecutive i.v. injections with 2 × 6, 
2 × 10, or 2 × 12.5 mg/kg of VMO-ex11 resulting in the depicted total dose of 12, 20, and 25 mg/kg, respectively, and sacrificed at day 4 after 
the first injection. (b) Blood L-Phe levels (mean ± SD), (c) RT-PCR analysis of Pah-mRNA from liver, indicating the estimated percent of exon 
skipping and (d) western blot analysis showing PAH protein levels in liver. The lower panel shows β-actin as loading control. (e) PAH enzyme 
activity in liver extracts relative to control wild-type levels (=100%; note that 23% of PAH activity is observed in heterozygous Pahenu2/+ mice).
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pseudoexon activation,11 and even PKU in which a pseu-
doexon within the PAH gene, albeit of unknown clinical rel-
evance, has recently been identified.24 It is assumed that 
the frequency of pseudoexon activating mutations is to date 
underestimated as transcript analysis is not usually per-
formed for genotyping, and complete intronic sequences 
are not generally included in standard sequencing analy-
sis. However, with the advent of next generation sequencing 
techniques deep intronic mutations will predictably be 
increasingly identified, as recent examples show.32–34 The 
approach can also be used for mutations causing activa-
tion of exonic or intronic cryptic splice sites, which are also 
frequent splicing defects. In this case, natural splice sites 
should be preserved so that blocking the cryptic splice site 
may effectively recover normal protein and activity.
Chemical composition of the oligonucleotide and delivery 
system clearly influence the biological potency and efficiency 
of in vivo antisense treatment. Both LNA and PMO/VMO 
have shown splice modulating activity in cells and animal 
models.7,13,35,36 The LNA oligonucleotide tested in the cellular 
model, although successfully transfected, was only partially 
effective, suggesting further sequence optimization or dos-
age increase may be necessary. In addition, the LNA is a 
15-mer and had matches to other genomic sequences which 
could also contribute to its only partial effect. In contrast, the 
PMOs tested contained 24 nucleotides and targeted exclu-
sively the PAH gene sequence. Although further studies are 
necessary to draw conclusions about the comparative effi-
ciencies of the two chemistries, our aim was to achieve com-
plete exon skipping in the PAH gene which was possible with 
PMO and VMO targeting conserved splice sites in cell culture 
and in mice. These results allow us to establish initial param-
eters for the future clinical application of splice modulation in 
human inborn metabolic disease. In cells, PMO resulted in 
efficient exon skipping at doses as low as 2.5 µmol/l for exon 
11, although higher doses were needed to achieve similar 
exon skipping levels for exon 12. This may be attributable to 
the fact that exon 12 has strong splice sites, while exon 11 
has a weak acceptor. Yet in mice, we did not observe any 
difference between VMO targeting exon 11 or exon 12 at the 
optimal dosage and regime tested (two consecutive i.v. injec-
tions with single doses of 12.5 mg/kg). Differences in AON 
uptake between cell transfection and in vivo delivery, genetic 
background or target cell type as well as species dependent 
pharmacokinetics, can influence splicing regulation and 
result in different effects in vivo and in vitro, as previously 
discussed.23
In the cellular model, a severe reduction of the amount of 
PAH protein was observed both with PMO-ex11 or PMO-
ex12 at 20 µmol/l although at the RNA levels exon skipping 
was not complete with PMO-ex12. These differences may 
be attributable to experimental reasons related to the tech-
niques used and the time point of analysis after transfection 
(24 hours for RNA, 48 hours for protein). In addition, skipping 
of exons 11 or 12 both produce an out-of-frame transcript 
but only in the case of exon 11 skipping is this transcript 
predicted to be subject to nonsense-mediated decay, as 
the premature termination codon introduced is located >50 
nucleotides upstream of an exon–exon junction.37 Indeed, 
in some experiments, transcript reduction is detectable for 
VMO-ex11 treatment, as compared to VMO-ex12.
Although the delivery of oligonucleotides into whole organ-
isms poses several challenges, we achieved 100% exon 
skipping in liver and kidney by simple tail vein injection, con-
sistent with earlier reports.8,38 Expression levels of the target 
gene are important for dosage and regime, as deduced from 
the comparison of the results we obtained in liver and kidney, 
where lower VMO amounts are needed for exon skipping in 
Figure 6 VMO targeting exon 11 or exon 12 exert the same 
biological effect. Heterozygous Pahenu2/+ mice (n = 1) were treated 
with two consecutive i.v. injections (of 12.5 mg/kg of VMO-ex11 
or VMO-ex12) and sacrificed at day 4 after the first injection. (a) 
Analysis of blood L-Phe levels (mean ± SD). (b) RT-PCR analysis 
of Pah-mRNA from liver, indicating the estimated percent of exon 
skipping. (c) Western blot analysis showing PAH protein levels in 
liver. The lower panel shows β-actin as loading control. (d) PAH 
enzyme activity in liver extracts relative to wild-type levels (=100%).
0
Day 0
i.v. VMO-Ex11
0 25 25
6% 92% 96% Exon skipping
PAH
PAH enzyme activity in % of wt
8–9–10 11 12 703 bp
587 bp
569 bp
13
12 13
11 138–9–10
8–9–10
β-actin
23% 0.9% 0.3%
0 25 0
mg/kg VMO-Ex12 (i.v.)
mg/kg VMO-Ex11 (i.v.)
Day 4
200
400
600
800
1,000
1,200
1,400
1,600
25 mg/kg VMO-Ex11
25 mg/kg VMO-Ex12
Ph
e 
le
ve
ls
 µ
m
o
l/l
a
b
c
d
Figure 7 Results in kidney from Pahenu2/+ mice treated with 
VMO-Ex11 or VMO-Ex12. Heterozygous Pahenu2/+ mice (n = 1) were 
treated with one or two consecutive injections (i.v. or i.p.) of 12.5 mg/
kg of vMO-ex11 or VMO-ex12. Mice were sacrificed at day 4 after 
the first injection. (a) RT-PCR analysis of Pah-mRNA from kidney, 
indicating the estimated percent of exon skipping, and (b) western 
blot analysis showing PAH protein levels in kidney. The lower panel 
shows β-actin as loading control. (c) PAH enzyme activity in kidney 
extracts relative to wild-type levels (=100%).
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kidney compared to liver, correlating with lower Pah expres-
sion levels and consequently fewer targets for exon skipping 
(Supplementary Figure S3).
It is important to work with the lowest possible effective 
dose to reduce the risk of off-target effects. Our model bio-
chemical endpoint measure was the achievement of high 
L-Phe levels (>1,200 µmol/l). The observation that suppres-
sion of liver PAH activity to less than 5% wild-type activity is 
necessary to cause hyperphenylalaninemia in mice agrees 
with previous reports.39,40 Complete exon skipping needed to 
achieve high L-Phe levels represents the extreme situation 
but from a therapeutic point of view, we can speculate that 
much lower amounts of splice switching may be relevant for 
many recessive-inherited diseases.
PMOs have been used in the mdx mouse model of DMD 
with excellent body-wide distribution and effect after systemic 
administration and promising results have also been reported 
in clinical trials. In DMD, entry of naked PMO is facilitated by 
the leaky nature of the membrane in the dystrophic muscle 
fibers.41 In enzyme deficiencies, responsible for inborn meta-
bolic diseases, a delivery agent is presumably needed for 
efficient cellular uptake. Different options include dendrimeric 
particles or cell penetrating peptides. The high toxicity of VMO 
immediately after i.v. injection was evident at the doses used 
(see Methods section) and surviving mice showed a decrease 
in the rate of weight gain. Although initial reports in the litera-
ture described no signs of toxicity with systemic VMO treat-
ment and no immune response after repeated applications,9 a 
recently published article described the contrary with high mor-
tality rates in treated mice, in line with our observations.28 The 
authors hypothesize that oligonucleotide hybridization resulting 
in an increase in cationic charge of the dendrimer moiety leads 
to blood clot formation which in turn induces cardiac arrest.28 
Indeed, the histopathology studies conducted in the mice that 
died during VMO treatment in our work showed large blood 
clots in the cardiac chambers, with dilation of both atria and 
ventricles, pulmonary congestion and alveolar edema. This 
supports the idea of cardiac arrest due to VMO-related alter-
ation of the clotting system as possible cause of death. The 
results clearly limit the potential of clinical application of VMO 
and favor future studies with other chemistries which have 
been shown to be well tolerated and without adverse effects. 
The in vivo assay system described in this work (targeting Pah 
exon 11 and monitoring L-Phe levels, Pah transcript and pro-
tein analysis) can be readily used in further studies comparing 
different chemistries and delivery agents available for clinical 
application for safe and efficient AON splice modulation.
Understanding the underlying mechanism in specific 
disease-causing mutations and developing drugs to correct 
them are a promising approach to treat genetic disorders, 
although rare diseases may pose difficulties for clinical 
application, including the high costs and the regulatory 
hurdles to overcome. Predictably, lessons learned from 
one disease can be translated to another related one. Here 
we report that AONs represent a powerful tool for splic-
ing modulation for a liver enzyme in a physiological context 
in living mice. In addition, we show that the exon-skipping 
approach for constitutive exons provides versatility for the 
rapid and easy generation of murine models of genetic 
diseases. A similar approach was recently described by 
intracerebroventricular injection of AONs to phenocopy 
a more severe and adult-onset forms of spinal muscular 
atrophy,22,23 providing several advantages for therapy test-
ing and characterization of distinctive pathological features 
of the different types of spinal muscular atrophy. With our 
results we confirm the potential of altering splicing of target 
genes expressed in tissues other than central nervous sys-
tem to generate a disease model.
In our model, repeated injections are needed to maintain the 
HPA phenotype, which is probably related to shorter half-lives 
of Pah-mRNA transcript and PAH protein. In this case, a vec-
torised approach providing sustained AON production such as 
the engineered AAV vectors expressing antisense sequences 
linked to U7 snRNA tested in DMD42 will be the best option to 
test. The exon-skipping approach may be very useful for patho-
physiologic studies modeling disease phenotypes of differing 
severity in addition to allowing evaluation of therapeutic effects. 
Antisense approaches may also be applied for better modeling 
of a severe form of the disease in existing model systems with a 
mild phenotype due to residual endogenous mRNA which can 
be targeted with specific AONs, or for in vivo study of protein 
isoforms by modulating skipping of alternative exons.
In summary, our work represents proof-of-concept for the 
in vivo use of antisense therapeutics for splicing defects in 
genetic disease, and for the potential of exon skipping in the 
flexible generation of animal models for such diseases.
Materials and methods
Cell culture and treatment. Human hepatoma Hep3B cells 
were cultured in standard conditions in MEM containing 
10% fetal bovine serum, 100 U/ml penicillin, 100 µg/ml 
streptomycin, and 2 mmol/l glutamine. One day prior to 
transfection, cells were seeded at 2 × 105 cells/ml in six-
well plates. Duplicate transfection experiments were per-
formed using morpholino (PMO) and locked nucleic acid 
(LNA) oligonucleotides. PMOs against the conserved splice 
sites of exons 11 and 12 of the human PAH gene as well 
as a scrambled (SC) oligonucleotide for negative control, 
were designed, synthesized, and purified by Gene Tools 
(Philomath, OR). LNA were designed and produced by 
Exiqon (Vedbaek, Denmark). Gene Tools and Exiqon offer a 
design service for exon skipping oligonucleotides, for which 
the researcher provides the exonic and flanking intronic 
sequences. In all cases, the oligonucleotides designed tar-
get the conserved 3′ or 5′ splice sites. The sequences of 
the different antisense oligonucleotides used are shown in 
Figure 1. Endo-Porter delivery reagent was used to deliver 
PMO to cultured cells following the manufacturer’s proto-
col (Gene Tools; www.gene-tools.com).13 For LNA, we used 
lipofectamine 2000 (Invitrogen, Carlsbad, CA) as transfec-
tion agent diluted in Opti-MEM I Reduced Serum Medium 
according to the manufacturer’s protocol.
Mice handling. All mice used, wild-type and heterozygous 
(Pahenu2/+), were in the C57Bl/6 background and were young 
adult males or females (4–12 weeks old; 18–28 g). Mice were 
maintained on standard chow. Animal experiments were car-
ried out in accordance with the State Veterinary Office of 
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Zurich and Swiss law on animal protection, the Swiss Federal 
Act on Animal Protection (1978), and the Swiss Animal Pro-
tection Ordinance (1981). All animal studies were approved 
by the Cantonal Veterinary Office, Zurich, and the Cantonal 
Committee for Animal Experiments, Zurich. Genotyping 
was performed with genomic DNA isolated from mouse ear 
biopsies and using the DNeasy Blood & Tissue kit (Qiagen, 
Hombrechtikon, Switzerland). Conventional PCR was per-
formed to amplify exon 7 of the mouse Pah gene (forward 
primer: 5′-CCTTGGGGAGTCATACCTCA-3′; reverse primer: 
5′-CGGTTCAGGTGTGTACATGG-3′). The amplified DNA 
was digested with the restriction enzyme Alw26I (Thermo 
Fisher Scientific, St Leon-Rot, Germany) to identify the 
mutated Pahenu2 allele carrying the mutation p.Phe263Ser 
(c.789T>C) that generates a restriction site for Alw26I.21,43
In vivo antisense treatment. Antisense Vivo-morpholinos (VMO, 
morpholinos covalently linked to an octaguanidine moiety) tar-
geting 5′ splice sites of exon 11 and 12 of the murine Pah gene 
were designed and supplied by Gene Tools. The sequences of 
the VMO used are shown in Figure 1. Mice were injected with 
different amounts of VMO from 6 to 50 mg/kg body weight, using 
i.p. or i.v. injections. Following the i.v. injection, Rimadyl (Pfizer) 
was administrated subcutaneously as a pain killer (5 mg/kg 
body weight). One to four mice per condition were tested in 
order to keep the number of animals as low as possible for pro-
tection of experimental animals. Mice were observed for ~15–20 
minutes to follow their recovery. All treated mice became tran-
siently lethargic following VMO injection. Approximately 20% of 
animals did not recover and perished within 12 hours following 
injection, which may be related to the formation of blood clots 
inducing cardiac arrest, as observed in histopathotogy studies 
postmortem and in line with previous observations.28
Sample collection, preparation, and L-Phe measure-
ment. For analysis of blood L-Phe levels, mice were fasted 
between 4–6 hours before blood collection. Blood was col-
lected from tail vein (~5 µl) or following decapitation on 
Guthrie filter cards and L-Phe concentration was deter-
mined using standard tandem mass spectrometry analysis 
as described.44 For RNA, protein and enzyme studies, the 
entire liver and both kidneys of each animal were excised 
immediately post euthanasia, placed in labeled cryotubes, 
snap-frozen in liquid nitrogen, and stored at −80 °C until pro-
cessed. Frozen tissues were pulverized using screws cooled 
in liquid N2, and tissue powder was stored at −80 °C until 
analysis. For enzyme activity and immunoquantification, liver 
powder was lysed at 4 °C in homogenizing buffer (10 µl/mg 
tissue) (50 mmol/l Tris-HClpH 7.5, 100 mmol/l KCl, 1 mmol/l 
EDTA, 1 mmol/l DL-Dithiothreitol, 1 µmol/l leupeptin, 1 µmol/l 
pepstatin, 200 µmol/l phenylmethanesulfonyl fluoride) using 
Qiagen TissueLyser II (Qiagen AG). After centrifugation at 
13,000 g at 4 °C for 30 minutes, supernatants were used to 
carry out PAH enzyme assays and were kept frozen at −80 
°C for immunoblotting. Protein concentration was determined 
using Bradford reagent.
PAH enzyme activity. PAH enzyme activity in liver extracts was 
measured according to a highly sensitive and quantitative assay 
using isotope-dilution liquid chromatography-electrospray 
ionization tandem mass spectrometry (LC-ESI-MSMS) as 
described.29 Briefly, assay conditions included preincubation at 
25 °C with L-Phe (1 mmol/l) for 4 minutes, then Fe(NH4)2(SO4)2 (100 ìmol/l) was added, and incubation was continued for one 
more min. After 5 minutes total preincubation time, BH4 (75 ìmol/l) 
was added to start the reaction. Between 2.5 and 5 µl (2.5–55 
µg) of total protein lysate extracted from mouse tissue was used. 
Reaction time was 2 minutes. The amount of L-Tyr produced 
was determined by LC with ESI-MSMS. Prior to analysis, the 
amino acids are derivatized to propyl chloroformate derivatives, 
using the commercially available PhenomenexEZ:faast kit. Pro-
tein concentrations were determined using Pyrogallol Red pro-
tein dye binding assay. Specific PAH activities are expressed in 
nmol L-Tyr produced per minute, per mg total protein.
RT-PCR. For in vitro studies after transfection with differ-
ent amounts of oligonucleotides, Hep3B cells were har-
vested at 24 hours and total RNA was isolated using Trizol. 
To amplify the human PAH-cDNA, total RNA was first 
reverse-transcribed with an oligo(dT) primer, followed by 
PCR amplification of the PAH gene region corresponding 
to exons 8–13 using the following primers: forward primer 
5′-CATGTGCCCTTGTTTTCAG-3′ and reverse primer 
5′-TTCACAGCTGACAGACCACA-3′.
For in vivo studies with mice, total RNA was isolated from 
20 to 30 mg of mouse liver tissue using QIAmp RNA blood 
mini kit (Qiagen) according to the manufacturer’s protocol. 
Random primed cDNA was prepared from 1 µg of total RNA 
using the Reverse Transcription kit (Promega, Wallisellen, 
Switzerland). PCR amplification of the region from exon 8 to 
exon 13 of the Pah-mRNA was performed using the following 
primers: forward primer 5′-CTAGTGCCCTTGTTTTCAGA-3′ 
and reverse primer 5′-AGGATCTACCACTGATGGGT-3′. 
Amplified products were separated by agarose gel electro-
phoresis and the excised bands analyzed by direct sequenc-
ing after extraction with QIAEX II Gel Extraction kit (Qiagen). 
The amplified PCR bands were quantified by densitometric 
analysis and reported as estimated percent exon skipping 
(relative to total amounts of amplified products in each lane).
Western blot. Quantification of PAH protein was performed 
by western blot analysis with whole mouse liver lysates 
or with cells harvested 48 hours after treatment. Equal 
amounts of lysed extracts (40 µg protein) were loaded on 
a 4–12% NuPAGE Novex Bis-Tris precast gel (Invitrogen). 
After electrophoresis, proteins were transferred to a nitro-
cellulose membrane (iBlot Gel Transfer Stacks, Regular) in 
an iBlot Gel transfer device (Invitrogen) for 7 minutes. Immu-
nodetection was carried out using commercially available 
anti-PAH antibody PH8 (Abcam, Cambridge, UK) followed 
by a second antibody goat anti-mouse-IgG-HRP (Santa 
Cruz Biotechnology, CA, USA). For loading control, mem-
branes were immunostained with either a polyclonal anti-
β-actin or a monoclonal anti-α-Tubulin antibody, produced 
in mouse (Sigma-Aldrich, St Louis, MO A2228 and T9026, 
respectively). Antibody binding was detected by enhanced 
chemiluminescence (Amersham ECL).
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Supplementary material
Figure S1. Antisense treatment of Hep3B cells for suppres-
sion of human PAH.
Figure S2. Time course analysis of the effects of the an-
tisense treatment on transcript, protein and L-Phe levels in 
heterozygous Pahenu2/+ mice.
Figure S3. Expression levels of PAH protein in liver and kid-
ney in heterozygous wt/enu2 mice untreated and treated with 
VMO-Ex11.
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